Direct GMP partnerships
Qualified manufacturing relationships with controlled technical and quality review.
Medicine.
Where it needs to be.
Qualified sourcing, regulatory readiness and controlled B2B distribution planning.
Regulated wholesale supply has not commenced.
Illustrative composition.
Not a NovaPharm product or active batch.
Qualified sourcingRegulatory disciplineQuality-led decisions
Sourcing strategy
Three routes. One standard.
Every route must meet the same evidence threshold.
Product-specific PLPI
Evidence-led assessment of appropriate parallel-import opportunities and obligations.
European sourcing
Diversified authorised supply routes with licence, quality and continuity checks.
Batch integrity
Evidence travels with the batch.
Clarity before complexity. Packaging, records and release status remain connected across each governed transaction.
Review the evidence boundaryRepresentative traceability composition. It is not a NovaPharm facility, product or active batch record.
Core focus
Specialist work. Less noise.
Oncology & specialty
Closer control of formulation, continuity and evidence.
Explore oncology continuityRegulatory & quality
Authorisation, QMS and vendor oversight before release.
Review regulatory servicesTechnology & traceability
Governed accounts, documents, evidence and decision history.
Explore technology controlsStart a qualified conversation